Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Lenvima/Keytruda Combo Misses OS Goal in 1st Line GI Cancer Trial
Eisai and Merck on January 24 reported mixed PIII trial results for their combination therapy of Lenvima (lenvatinib) and Keytruda (pembrolizumab), missing one of the study’s main goals of overall survival (OS) extension in certain gastroesophageal cancer. The readout was…
To read the full story
Related Article
- Lenvima-Keytruda Combo’s Liver Cancer Trial Halted after OS Miss
October 31, 2025
BUSINESS
- Amvuttra Key to Alnylam Japan’s 25%-Plus CAGR Goal through 2030
August 20, 2026
- Biogen Japan President Den Tapped as Chief of Staff to Global CEO
August 20, 2026
- Moderna’s mNEXSPIKE Grabs Japan Approval for XFG Variant
August 20, 2026
- Nipro’s Forxiga AG to Hit Shelves on September 4
August 20, 2026
- Teijin Taps CAR-T Expert Campana as Technical Advisor
August 20, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…